Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.

PubWeight™: 6.83‹?› | Rank: Top 1%

🔗 View Article (PMID 19339045)

Published in Lancet on March 30, 2009


Indian Polycap Study (TIPS), S Yusuf, P Pais, R Afzal, D Xavier, K Teo, J Eikelboom, A Sigamani, V Mohan, R Gupta, N Thomas

Associated clinical trials:

The Indian POLYCAP Study (TIPS) | NCT00443794

Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians Using a Single PolyPill (PolyIran) | NCT01271985

Fixed Combination for Lipid and Blood Pressure Control (FILIP) | NCT03047538

Articles citing this

Presentation, management, and outcomes of 25 748 acute coronary syndrome admissions in Kerala, India: results from the Kerala ACS Registry. Eur Heart J (2012) 2.90

Acceptance of a Polypill approach to prevent cardiovascular disease among a sample of U.S. physicians. Prev Med (2010) 2.36

Fixed-dose combination therapy for the prevention of cardiovascular disease. Cochrane Database Syst Rev (2014) 2.24

The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysis. PLoS One (2013) 1.95

Prevalence, awareness and risk factors of hypertension in a large cohort of Iranian adult population. J Hypertens (2013) 1.86

Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. Circulation (2011) 1.77

Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Des Devel Ther (2011) 1.68

Randomized Polypill crossover trial in people aged 50 and over. PLoS One (2012) 1.64

Polypill therapy, subclinical atherosclerosis, and cardiovascular events-implications for the use of preventive pharmacotherapy: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol (2013) 1.60

Screening for future cardiovascular disease using age alone compared with multiple risk factors and age. PLoS One (2011) 1.56

Clustering of chronic non-communicable disease risk factors among selected Asian populations: levels and determinants. Glob Health Action (2009) 1.53

Resource Effective Strategies to Prevent and Treat Cardiovascular Disease. Circulation (2016) 1.40

Can the polypill save the world from heart disease? Lancet (2009) 1.35

An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk. PLoS One (2011) 1.34

Hypertension management using mobile technology and home blood pressure monitoring: results of a randomized trial in two low/middle-income countries. Telemed J E Health (2012) 1.34

No identifiable Hb1Ac or lifestyle change after a comprehensive diabetes programme including motivational interviewing: a cluster randomised trial. Scand J Prim Health Care (2013) 1.29

CARRS Surveillance study: design and methods to assess burdens from multiple perspectives. BMC Public Health (2012) 1.27

A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization. Trials (2011) 1.27

Potential impact of single-risk-factor versus total risk management for the prevention of cardiovascular events in Seychelles. Bull World Health Organ (2011) 1.23

Macroeconomic implications of population ageing and selected policy responses. Lancet (2014) 1.12

Medical care and payment for diabetes in China: enormous threat and great opportunity. PLoS One (2012) 1.10

Impact of age and sex on primary preventive treatment for cardiovascular disease in the West Midlands, UK: cross sectional study. BMJ (2012) 1.08

Stroke: working toward a prioritized world agenda. Stroke (2010) 1.05

Screening for cardiovascular disease using age alone: reflections on a paper peer-reviewed as both 'radical' and 'unsurprising'. J Med Screen (2011) 1.05

Utility of genetic determinants of lipids and cardiovascular events in assessing risk. Nat Rev Cardiol (2011) 1.04

The Indian Polycap Study (TIPS). Lancet (2009) 1.03

Stroke: working toward a prioritized world agenda. Cerebrovasc Dis (2010) 1.01

The efficacy and tolerability of 'polypills': meta-analysis of randomised controlled trials. PLoS One (2012) 1.00

The Prevention of Global Chronic Disease: Academic Public Health's New Frontier. Am J Public Health (2011) 0.99

Management of NCD in low- and middle-income countries. Glob Heart (2014) 0.97

A systematic review of economic evaluations of interventions to tackle cardiovascular disease in low- and middle-income countries. BMC Public Health (2012) 0.94

Qi-shen-yi-qi dripping pills for the secondary prevention of myocardial infarction: a randomised clinical trial. Evid Based Complement Alternat Med (2013) 0.93

Multidrug treatment of type 2 diabetes: a challenge for compliance. Diabetes Care (2011) 0.92

Characteristics of high risk people with cardiovascular disease in Chinese rural areas: clinical indictors, disease patterns and drug treatment. PLoS One (2013) 0.91

Scaling up chronic disease prevention interventions in lower- and middle-income countries. Annu Rev Public Health (2013) 0.91

The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population. BMJ Open (2011) 0.90

Projected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects. Am Heart J (2011) 0.90

Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence. Nat Rev Cardiol (2010) 0.89

Hotline sessions presented at the American College of Cardiology Congress 2009. Clin Res Cardiol (2009) 0.88

Cardiovascular disease risk reduction in rural China: a clustered randomized controlled trial in Zhejiang. Trials (2013) 0.87

Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trial. PLoS One (2012) 0.85

Prevalence and associated factors of polypharmacy among adult Saudi medical outpatients at a tertiary care center. J Family Community Med (2013) 0.84

Stroke: working toward a prioritized world agenda. Int J Stroke (2010) 0.84

Process Pharmacology: A Pharmacological Data Science Approach to Drug Development and Therapy. CPT Pharmacometrics Syst Pharmacol (2016) 0.82

Efficacy-oriented compatibility for component-based Chinese medicine. Acta Pharmacol Sin (2015) 0.82

Drug therapies for the primary prevention of cardiovascular events: trials and errors: 2009 Ancel Keys Memorial Lecture. Circulation (2010) 0.81

What is the future of stroke prevention?: debate: polypill versus personalized risk factor modification. Stroke (2010) 0.80

CVD screening in low-risk, asymptomatic adults: clinical trials needed. Nat Rev Cardiol (2012) 0.80

Antiplatelet combinations for prevention of atherothrombotic events. Vasc Health Risk Manag (2011) 0.79

Differences in primary health care delivery to Australia's Indigenous population: a template for use in economic evaluations. BMC Health Serv Res (2012) 0.79

Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction. Health Serv Res (2012) 0.79

Stroke Risk Factors, Genetics, and Prevention. Circ Res (2017) 0.78

Access to Medications for Cardiovascular Diseases in Low- and Middle-Income Countries. Circulation (2016) 0.78

Use of medications and lifestyles of hypertensive patients with high risk of cardiovascular disease in rural China. PLoS One (2015) 0.78

Polypill improves adherence but fails to win all scientists' hearts. Nat Med (2013) 0.77

Effect of Pollypill on cardiovascular parameters: Systematic review and meta-analysis. J Cardiovasc Dis Res (2013) 0.77

The Indian Polycap Study (TIPS). Lancet (2009) 0.76

Lipid lowering: education is key. Nat Rev Cardiol (2009) 0.75

Construction of a three-dimensional model of cardiovascular disease and deployment of a new method of fostering patient adherence to instruction. Patient Prefer Adherence (2013) 0.75

The polypill story from a ringside seat. J R Soc Med (2009) 0.75

Could patents interfere with the development of a cardiovascular polypill? J Transl Med (2016) 0.75

Novel treatments for cardiovascular disease prevention. Cardiovasc Ther (2011) 0.75

The United States and global health: inseparable and synergistic? The Institute of Medicine's report on global health. Glob Health Action (2009) 0.75

The fate of medications evaluated for ischemic stroke pharmacotherapy over the period 1995-2015. Acta Pharm Sin B (2016) 0.75

Implementing and sustaining a mobile medical clinic for prenatal care and sexually transmitted infection prevention in rural Mysore, India. BMC Infect Dis (2017) 0.75

Developing therapies for the metabolic syndrome: challenges, opportunities, and… the unknown. Ther Adv Endocrinol Metab (2010) 0.75

Facts and ideas from anywhere. Proc (Bayl Univ Med Cent) (2009) 0.75

Quality Improvement for Cardiovascular Disease Care in Low- and Middle-Income Countries: A Systematic Review. PLoS One (2016) 0.75

From rapalogs to anti-aging formula. Oncotarget (2017) 0.75

Type 2 diabetes and cardiovascular diseases: do they share a common soil? The Asian Indian experience. Heart Asia (2012) 0.75

Combining antihypertensive and antihyperlipidemic agents - optimizing cardiovascular risk factor management. Integr Blood Press Control (2011) 0.75

Fixed-dose combination therapy for the prevention of cardiovascular disease. Cochrane Database Syst Rev (2012) 0.75

The Indian Polycap Study (TIPS). Lancet (2009) 0.75

Implementation of a comprehensive intervention for patients at high risk of cardiovascular disease in rural China: A pragmatic cluster randomized controlled trial. PLoS One (2017) 0.75

Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease. PLoS One (2017) 0.75

Articles by these authors

The phylogeny of prokaryotes. Science (1980) 24.57

Detailed analysis of the higher-order structure of 16S-like ribosomal ribonucleic acids. Microbiol Rev (1983) 23.08

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med (2001) 20.20

Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis (1985) 19.03

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet (2006) 15.32

Timing the ancestor of the HIV-1 pandemic strains. Science (2000) 10.42

Secondary structure model for bacterial 16S ribosomal RNA: phylogenetic, enzymatic and chemical evidence. Nucleic Acids Res (1980) 9.50

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet (2006) 9.43

Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J (1985) 9.28

The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care (1999) 9.16

Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA (2001) 8.80

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet (2001) 8.54

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med (1992) 8.38

Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE) Lancet (2000) 8.01

Why do we need some large, simple randomized trials? Stat Med (1985) 7.67

Secondary structure model for 23S ribosomal RNA. Nucleic Acids Res (1981) 7.12

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet (2008) 7.05

Human gene mutation database-a biomedical information and research resource. Hum Mutat (2000) 6.87

An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation (1989) 6.87

Matching using estimated propensity scores: relating theory to practice. Biometrics (1996) 6.73

Emerging epidemic of cardiovascular disease in developing countries. Circulation (1998) 6.41

Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med (2001) 6.38

Community-based treatment of advanced HIV disease: introducing DOT-HAART (directly observed therapy with highly active antiretroviral therapy). Bull World Health Organ (2001) 6.07

Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med (1988) 5.81

Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA (1995) 5.80

High prevalence of diabetes and impaired glucose tolerance in India: National Urban Diabetes Survey. Diabetologia (2001) 5.79

Sequence of the 16S Ribosomal RNA from Halobacterium volcanii, an Archaebacterium. Science (1983) 5.66

Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: phase I results of the Indian Council of Medical Research-INdia DIABetes (ICMR-INDIAB) study. Diabetologia (2011) 5.62

Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. J Assoc Physicians India (2009) 5.45

Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet (2000) 5.00

The phylogeny of purple bacteria: the alpha subdivision. Syst Appl Microbiol (1984) 4.96

Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity. Science (2011) 4.72

Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis (2005) 4.57

The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia (2005) 4.45

Risk factors for acute myocardial infarction in Indians: a case-control study. Lancet (1996) 4.28

Screening for Down's syndrome: effects, safety, and cost effectiveness of first and second trimester strategies. BMJ (2001) 4.15

Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy. Nature (1986) 4.13

Were the original eubacteria thermophiles? Syst Appl Microbiol (1987) 4.06

Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators. JAMA (1993) 4.01

Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation (2001) 3.96

Mianserin hydrochloride: a novel antidepressant. Br J Psychiatry (1976) 3.92

X-linked anhidrotic (hypohidrotic) ectodermal dysplasia is caused by mutation in a novel transmembrane protein. Nat Genet (1996) 3.90

Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet (1998) 3.79

Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet (2002) 3.77

Rooting the archaebacterial tree: the pivotal role of Thermococcus celer in archaebacterial evolution. Syst Appl Microbiol (1988) 3.76

Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation (1990) 3.72

Factors affecting uptake of antenatal HIV testing in London: results of a multicentre study. BMJ (1998) 3.72

Coronary heart disease and its risk factors in first-generation immigrant Asian Indians to the United States of America. Indian Heart J (1996) 3.66

Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med (1999) 3.63

Putative introns in tRNA genes of prokaryotes. Proc Natl Acad Sci U S A (1983) 3.60

Epidemiology and causation of coronary heart disease and stroke in India. Heart (2008) 3.60

Health and peace: time for a new discipline. Lancet (2001) 3.52

Awareness and knowledge of diabetes in Chennai--the Chennai Urban Rural Epidemiology Study [CURES-9]. J Assoc Physicians India (2005) 3.46

Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. N Engl J Med (2000) 3.32

Analgesic efficacy of pre-operative stellate ganglion block on postoperative pain relief: a randomised controlled trial. Anaesthesia (2014) 3.30

Halobacterium volcanii tRNAs. Identification of 41 tRNAs covering all amino acids, and the sequences of 33 class I tRNAs. J Biol Chem (1984) 3.25

Sequence of the 16S rRNA gene from the thermoacidophilic archaebacterium Sulfolobus solfataricus and its evolutionary implications. J Mol Evol (1985) 3.20

Cardiovascular and cancer mortality among Canadians of European, south Asian and Chinese origin from 1979 to 1993: an analysis of 1.2 million deaths. CMAJ (1999) 3.18

Risk factors, atherosclerosis, and cardiovascular disease among Aboriginal people in Canada: the Study of Health Assessment and Risk Evaluation in Aboriginal Peoples (SHARE-AP). Lancet (2001) 3.16

Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation (2000) 3.12

Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ (1996) 2.90

Prevalence of coronary artery disease in Asian Indians. Am J Cardiol (1992) 2.90

Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost (2011) 2.87

Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis (2004) 2.87

Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin Infect Dis (2000) 2.87

Is the 'rule of halves' in hypertension still valid?--Evidence from the Chennai Urban Population Study. J Assoc Physicians India (2003) 2.86

Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials. BMJ (1991) 2.81

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation (1999) 2.79

Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation (2007) 2.76

Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet (2000) 2.74

Structural basis for the recognition of DNA repair proteins UNG2, XPA, and RAD52 by replication factor RPA. Cell (2000) 2.73

Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation (1994) 2.61

Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet (2005) 2.56

Prediction of human protein function according to Gene Ontology categories. Bioinformatics (2003) 2.54

Interpreting hospital mortality data. The role of clinical risk adjustment. JAMA (1989) 2.53

The Chennai Urban Rural Epidemiology Study (CURES)--study design and methodology (urban component) (CURES-I). J Assoc Physicians India (2003) 2.50

Limb-salvage treatment versus amputation for osteosarcoma of the distal end of the femur. J Bone Joint Surg Am (1986) 2.49

Transcription and excision of a large intron in the tRNATrp gene of an archaebacterium, Halobacterium volcanii. J Biol Chem (1985) 2.45

Differential inhibition of signaling pathways by dominant-negative SH2/SH3 adapter proteins. Mol Cell Biol (1995) 2.44

The safety and efficacy of prophylactic ondansetron in patients undergoing modified radical mastectomy. Anesth Analg (1999) 2.42

ACC/AHA Guidelines for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery). American College of Cardiology/American Heart Association. J Am Coll Cardiol (1999) 2.35

Mutations in the homeobox gene HESX1/Hesx1 associated with septo-optic dysplasia in human and mouse. Nat Genet (1998) 2.34

Treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex. Br Med J (Clin Res Ed) (1986) 2.33

The antioxidant vitamins and cardiovascular disease. A critical review of epidemiologic and clinical trial data. Ann Intern Med (1995) 2.32

Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation (2001) 2.30

D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics (1997) 2.28

Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ (1989) 2.27

Overview of randomised trials of diuretics in pregnancy. Br Med J (Clin Res Ed) (1985) 2.27

The need for obtaining accurate nationwide estimates of diabetes prevalence in India - rationale for a national study on diabetes. Indian J Med Res (2011) 2.26

Appearing and disappearing CT scan abnormalities and seizures. J Neurol Neurosurg Psychiatry (1985) 2.26

Physiological basis of myocardial contrast enhancement in fast magnetic resonance images of 2-day-old reperfused canine infarcts. Circulation (1995) 2.24

Prevalence of metabolic syndrome using WHO, ATPIII and IDF definitions in Asian Indians: the Chennai Urban Rural Epidemiology Study (CURES-34). Diabetes Metab Res Rev (2007) 2.24

Activation of Pak by membrane localization mediated by an SH3 domain from the adaptor protein Nck. Curr Biol (1997) 2.24

An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet (2006) 2.23

Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group. J Am Coll Cardiol (2000) 2.22